Cingulate Inc. (CING)
NASDAQ: CING · Real-Time Price · USD
4.147
+0.227 (5.78%)
Oct 1, 2025, 3:19 PM EDT - Market open
Company Description
Cingulate Inc., a biopharmaceutical company, develops pharmaceutical products using delivery platform technology for the treatment of attention deficit/hyperactivity disorder (ADHD) and anxiety in the United States.
The company’s lead product candidate is CTx-1301 (dexmethylphenidate), which is in Phase 3 clinical trials.
It also develops CTx-2103 (buspirone) that is in a formulation stage for the treatment of anxiety and mental health disorders; and plans to initiate the clinical plan for CTx-1302 (dextroamphetamine) to treat ADHD in children, adolescents, and adults.
Cingulate Inc. was founded in 2012 and is headquartered in Kansas City, Kansas.
Cingulate Inc.
Country | United States |
Founded | 2012 |
IPO Date | Dec 8, 2021 |
Industry | Biotechnology |
Sector | Healthcare |
Employees | 13 |
CEO | Jennifer Callahan |
Contact Details
Address: 1901 West 47th Place Kansas City, Kansas 66205 United States | |
Phone | 913 942 2300 |
Website | cingulate.com |
Stock Details
Ticker Symbol | CING |
Exchange | NASDAQ |
Stock Type | Common Stock |
Fiscal Year | January - December |
Reporting Currency | USD |
IPO Price | $6.00 |
CIK Code | 0001862150 |
CUSIP Number | 17248W105 |
ISIN Number | US17248W3034 |
Employer ID | 86-3825535 |
SIC Code | 2834 |
Key Executives
Name | Position |
---|---|
Dr. Shane J. Schaffer Pharm.D. | Co-Founder, Chief Executive Officer and Chairman of the Board (Leave of Absence) |
Jennifer L. Callahan CPA | Interim Chief Executive Officer, Senior Vice President, Chief Financial Officer and Secretary |
John A. Roberts M.B.A. | Executive Chairman |
Dr. Raul R. Silva M.D. | Co-Founder, Executive Vice President and Chief Science Officer |
Dr. Matthew N. Brams M.D. | Co-Founder, Executive Vice President and Chief Medical Officer |
Thomas Dalton | Vice President of Investor and Public Relations |
Nilay Patel J.D. | Chief Legal Officer |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Sep 25, 2025 | 8-K | Current Report |
Sep 5, 2025 | 8-K | Current Report |
Aug 28, 2025 | 8-K | Current Report |
Aug 19, 2025 | 10-Q | Quarterly Report |
Aug 19, 2025 | 8-K | Current Report |
Aug 15, 2025 | DEF 14A | Other definitive proxy statements |
Aug 15, 2025 | NT 10-Q | Notification of inability to timely file Form 10-Q or 10-QSB |
Aug 15, 2025 | 8-K | Current Report |
Aug 8, 2025 | 8-K | Current Report |
Aug 6, 2025 | 8-K | Current Report |